Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy

Background: To compare chronological changes in lower urinary tract symptoms (LUTS) after low-dose-rate prostate extended-release therapy (LDR-BT) using the overactive bladder symptom score (OABSS) in patients aged ≥ 75 years (elderly group) versus those aged < 75 years (control group). Materials and Methods: Patients with prostate cancer who underwent LDR-BT at Gifu University Hospital were included in this study. The International Prostate Symptom Score (IPSS), OABSS, and quality of life-based on urinary symptoms (IPSS-QOL) were evaluated before and after LDR-BT. We compared chronological changes in IPSS, OABSS, and IPSS-QOL in the elderly group with those in the control group and assessed the association between the resolution of OABSS and clinicopathological covariates. Results: A total of 484 patients were enrolled in this study. In the elderly group, the total IPSS, OABSS, and frequency scores increased at 1 month postoperatively, whereas the control group showed an increase at 3 months postoperatively. Multivariate analysis identified changes from baseline to the maximum OABSS and pre-treatment OABSS as significant predictors of delayed resolution of OABSS after LDR-BT. Conclusions: Changes in pre-treatment OABSS and pre- and post-LDR-BT OABSS values were independent predictors of delayed resolution of OABSS; however, no correlation was found with age.

[1]  M. Nakano,et al.  Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center , 2022, Prostate international.

[2]  K. Amano,et al.  Changes in quality of life and lower urinary tract symptoms over time in cancer patients after a total prostatectomy: systematic review and meta-analysis , 2021, Supportive Care in Cancer.

[3]  B. Frizzell,et al.  Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy. , 2021, Brachytherapy.

[4]  T. Shiraishi,et al.  Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly , 2020, Clinical and Translational Radiation Oncology.

[5]  M. Matsuo,et al.  Assessment of long-term changes in lower urinary tract symptoms in patients with prostate cancer who underwent low-dose-rate prostate brachytherapy. , 2020, Urology.

[6]  M. Hasegawa,et al.  Low‐dose‐rate brachytherapy for prostate cancer: A 15‐year experience in Japan , 2020, International journal of urology : official journal of the Japanese Urological Association.

[7]  N. Katayama,et al.  Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). , 2019, Brachytherapy.

[8]  P. Heathcote,et al.  Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling , 2019, BJU international.

[9]  T. Sugihara,et al.  Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot‐assisted radical prostatectomy , 2019, Neurourology and urodynamics.

[10]  S. Anai,et al.  Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer , 2018, Clinical and translational radiation oncology.

[11]  S. Anai,et al.  Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute , 2017, BMC Urology.

[12]  N. Shigematsu,et al.  Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score. , 2017, Brachytherapy.

[13]  R. Saskin,et al.  Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[14]  Yu-hua Lin,et al.  Lower urinary tract symptoms of prostate cancer patients undergoing treatments over eight-month follow-up. , 2015, Journal of clinical nursing.

[15]  S. Anai,et al.  Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy , 2013, Radiation oncology.

[16]  W. J. Morris,et al.  Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. , 2009, International journal of radiation oncology, biology, physics.

[17]  Howard Pai,et al.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.

[18]  N. Shigematsu,et al.  Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy. , 2007, Brachytherapy.

[19]  G. Pond,et al.  The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. , 2007, Brachytherapy.

[20]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[21]  R. Stock,et al.  Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation , 2006, BJU international.

[22]  Y. Homma,et al.  Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.

[23]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[24]  J. Battermann,et al.  Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. , 2005, International journal of radiation oncology, biology, physics.

[25]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[26]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[27]  R. Stock,et al.  Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. , 2012, The Journal of urology.